MRNA: Moderna, Inc. Forward P/S Multiple

Public company logo of Moderna, Inc. (MRNA)

Moderna, Inc. (MRNA) bases its foundation on flexible mRNA technology, which enables the rapid development of new drugs. The forward P/S trend visualizes the market reaction to these drivers, where the value of 37.10 serves as the current metric. Stable capacity utilization at drug manufacturing plants supports the share price, although geopolitical tensions and challenges with government procurement create risks for global product distribution.

MRNA Moderna: Market Cap to Future Revenue Ratio in the range 07/04/2022 - 11/13/2026

Analytical breakdowns for Moderna, Inc.

- stock price and consensus target price:
Stock Quotes Moderna|MRNA - Analyst Forecast Prices
- market capitalization information:
Market Capitalization Moderna Therapeutics|MRNA - Company Buyout Price
- issuer book value statistics:
Net Assets per Single Share Moderna|MRNA - Total Stockholders' Equity|Market Value to Book Value Ratio modernatx.com|MRNA - Total Business Assets
- company liabilities and liquidity data:
Debt to Equity Moderna, Inc.|MRNA - Ratio of Long-Term Indebtedness to Capital|Short-Term Debt to Equity Moderna, Inc.|MRNA - Company Total Debt|Debt to Book Capitalization Ratio Moderna Therapeutics|MRNA - Long-Term Debt|Company Short-Term Debts Moderna|Quick Ratio modernatx.com
- business earnings and investment ratios data:
MRNA - Company Net Income|Expected Profit Moderna, Inc.|MRNA - Company Value to Net Income|Future Price to Earnings Moderna Corp|MRNA - Growth-Adjusted P/E Ratio|EV/EBITDA Multiple Moderna Therapeutics|MRNA - Operating profit EBITDA|Net earnings per share for the last 12 months Moderna|MRNA - Earnings per share for the trailing year|Quarterly EPS earnings growth modernatx.com|MRNA - Expected net earnings per share growth this year|Net earnings per share growth forecast for next year Moderna, Inc.
- revenue and sales details:
MRNA - Company Sales Volume|Projected Sales Volume Moderna|MRNA - Market Cap to Revenue|Forward Price-to-Revenue Multiple Moderna Therapeutics
Analysis of all company metrics:MRNA (Moderna)
Original product of Moderna, Inc.

Moderna, Inc. (MRNA) revenues are driven by the epidemiological landscape and seasonal demand, remaining independent of macroeconomic cycles. Under these conditions, the company's forward P/S ratio allows for a comparison of current market value against projected revenue for the coming year. This multiple measures the premium for future sales growth, where inflated values signal the risk of overpaying for expected but not yet realized earnings.

Competitor analysis

Summit Therapeutics Inc. - Forward Price-to-Revenue Multiple|Price to Expected Revenue Ratio PCVX (Vaxcyte Inc)|Tarsus Pharma - Forward P/S Multiple|Market Cap to Expected Sales Ratio CorMedix Therapeutics CRMD|Seres Therapeutics (MCRB) - Price-to-Projected Revenue Ratio|Market Cap to Future Revenue Ratio sperotherapeutics.com (SPRO)|Price-to-Projected Revenue Ratio SCYNEXIS Inc|Market Cap to Projected Revenue ANTX (AN2 Bio)|Price-to-Projected Revenue Ratio PolyPid Ltd. (PYPD)|Market Cap to Expected Sales Ratio YS Biopharma Co., Ltd.|Price-to-Projected Revenue Ratio Iterum Therapeutics ITRM|PHGE - Forward Price-to-Revenue Multiple|SNGX - Price-to-Projected Revenue Ratio|Market Cap to Future Revenue Ratio 60 Degrees Pharmaceuticals|OGEN: Forward P/S Multiple|Market Cap to Projected Revenue OPGN